HC Wainwright Cuts Astria Therapeutics (NASDAQ:ATXS) Price Target to $16.00

Astria Therapeutics (NASDAQ:ATXS) had its target price cut by HC Wainwright from $18.00 to $16.00 in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other research firms have also recently weighed in on ATXS. Wedbush restated an outperform rating and set a $17.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, March 26th. Jefferies Financial Group increased their target price on shares of Astria Therapeutics from $22.00 to $27.00 and gave the company a buy rating in a research report on Monday, March 25th.

Astria Therapeutics Price Performance

ATXS opened at $9.17 on Tuesday. The firm has a fifty day moving average price of $13.21 and a 200 day moving average price of $9.27. Astria Therapeutics has a 1 year low of $4.26 and a 1 year high of $16.90. The stock has a market cap of $503.52 million, a P/E ratio of -3.92 and a beta of 0.69.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.08). Equities analysts expect that Astria Therapeutics will post -1.55 EPS for the current year.

Insider Activity at Astria Therapeutics

In related news, insider Christopher Morabito sold 9,200 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $11.15, for a total value of $102,580.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Perceptive Advisors Llc bought 2,481,350 shares of the stock in a transaction on Thursday, February 1st. The stock was bought at an average price of $12.09 per share, with a total value of $29,999,521.50. Following the completion of the purchase, the director now directly owns 4,873,721 shares in the company, valued at approximately $58,923,286.89. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christopher Morabito sold 9,200 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $11.15, for a total transaction of $102,580.00. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Perceptive Advisors LLC boosted its stake in Astria Therapeutics by 82.9% during the fourth quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after buying an additional 1,814,608 shares during the period. Vivo Capital LLC lifted its position in shares of Astria Therapeutics by 47.7% during the fourth quarter. Vivo Capital LLC now owns 2,482,727 shares of the biotechnology company’s stock worth $19,067,000 after purchasing an additional 801,528 shares in the last quarter. Armistice Capital LLC acquired a new stake in shares of Astria Therapeutics during the fourth quarter worth about $12,119,000. Affinity Asset Advisors LLC lifted its position in shares of Astria Therapeutics by 46.6% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,466,465 shares of the biotechnology company’s stock worth $11,262,000 after purchasing an additional 466,165 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Astria Therapeutics during the fourth quarter worth about $1,469,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.